Our phytocannabinoid-based products are aimed at improving the lives of people battling Alzheimer’s disease, Parkinson’s disease, chronic pain, PTSD, and eating disorders.

We are developing four proprietary phytocannabinoid-based products including our most advanced novel formulation for Alzheimer’s, called Hyalolex

Dr. Chuanhai Cao, Associate Professor of Pharmacy at the University of South Florida is a renowned Alzheimer’s researcher. He discovered that THC, the psychoactive cannabinoid found in the cannabis plant, in combination with other formulations, helps slow down the build-up of plaque in the brain that is a hallmark of Alzheimer’s disease. Hyalolex, which helps alleviate several end points of the disease, is based on Dr. Cao’s and other independent research.

Dr. Chuanhai Cao was interviewed by Dr. Sanjay Gupta for CNN’s Weed 3.

We are leaders in phytocannabinoid-based combination therapies with a portfolio of seven patents filed with the United States Patent and Trademark Office (“USPTO”), for indications of Alzheimer’s, Parkinson’s, pain, seizures, and eating disorders.Our most advanced formulation for indications of Alzheimer’s is available in Puerto Rico and will be available to people of other legal U.S. states in 2018.